Researchers develop vaccine that stops Alzheimer’s in miceMay 20th, 2008 - 1:24 pm ICT by admin
Washington, May 20 (ANI): Researchers from University of Rochester Medical Centre have developed a new vaccine, which triggers an immune response that may protect against Alzheimer’s without causing inflammation or significant side effects.
The team conducted their study using a mouse model with Alzheimer’s-like pathology and found that the vaccinated mice generated an immune response to the protein known as amyloid-beta peptide, which accumulates in what are called “amyloid plaques” in brains of people with Alzheimer’s.
The vaccinated mice demonstrated normal learning skills and functioning memory in spite of being genetically designed to develop an aggressive form of the disease.
“Our study demonstrates that we can create a potent but safe version of a vaccine that utilizes the strategy of immune response shaping to prevent Alzheimer’s-related pathologies and memory deficits,” said William Bowers lead author and Associate professor of neurology and of microbiology and immunology at the Medical Centre.
“The vaccinated mice not only performed better, we found no evidence of signature amyloid plaque in their brains,” he added.
For the vaccine, Bowers’ team used a herpes virus that is stripped of the viral genes that can cause disease or harm. They then load the virus container with the genetic code for amyloid beta and interleukin-4, a protein that stimulates immune responses involving type 2 T helper cells, which are lymphocytes that play an important role in the immune system.
Key features of the disease included accumulation of amyloid plaques in the brains of patients and the loss of normal functioning tau, a protein that stabilizes the transport networks in neurons.
Prior to vaccine study, the mice were trained to navigate a maze using spatial clues.
They were then tested periodically during the 10-month study on the amount of time and distance travelled to an escape pod and the number of errors made along the way.
“What we found exciting was that by targeting one pathology of Alzheimer’s - amyloid beta - we were able to also prevent the transition of tau from its normal form to a form found in the disease state,” said Bowers.
“We have learned a great deal from this ongoing project.
“Importantly, it has demonstrated the combined strengths of the gene delivery platform and the immune shaping concept for the creation of customized vaccines for Alzheimer’s disease, as well as a number of other diseases.
“We are currently working on strategies we believe can make the vaccine even safer,” he added.
The study appears in May issue of Molecular Therapy, the journal of The American Society of Gene Therapy. (ANI)
- Novel gene therapy shows promise against Alzheimer's - Mar 05, 2011
- Proteins responsible for Alzheimer's 'may spread through infection' - Oct 22, 2010
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- Sleep disorders are early signs of Alzheimer's - Sep 06, 2012
- Chronic high cholesterol diet leads to brain damage: Study - Nov 25, 2010
- Potent new vaccine found effective against Alzheimer's - Jun 08, 2012
- Drug reverses Alzheimer's symptoms in mice: Study - Feb 10, 2012
- Scientists eliminate plaque formation in Alzheimer's - Sep 06, 2012
- Tobacco-derived compound prevents memory loss in Alzheimer's - Apr 28, 2011
- Asthma drug could help fight Alzheimer's - Mar 27, 2011
- How Alzheimer's plaques lead to loss of nitric oxide in brain - Jan 11, 2011
- Novel mouse gene could lead to new Alzheimer's treatments - Nov 12, 2009
- High cholesterol linked to Alzheimer's - Sep 13, 2011
- Asthma drug could help fight Alzheimer's disease - Mar 26, 2011
- Turmeric-based drug being tested against Alzheimer's - Feb 15, 2012
Tags: amyloid plaques, genetic code, helper cells, herpes virus, immune response, immune responses, interleukin, lymphocytes, medical centre, memory deficits, microbiology and immunology, mouse model, pathologies, rochester medical, time and distance, transport networks, university of rochester, vaccine study, viral genes, william bowers